A provider briefing on Cyltezo Pen availability in 2026. Understand the supply landscape, prescribing implications, and tools to help your patients.
As a prescriber of biologic therapies, you've likely heard from patients struggling to fill their Cyltezo (adalimumab-dbll) prescriptions. While Cyltezo is not experiencing a traditional manufacturing shortage, the reality on the ground is that many patients face significant barriers to access.
This briefing covers the current supply landscape, prescribing considerations, and practical tools to help your patients maintain uninterrupted TNF-inhibitor therapy.
Understanding the current situation requires context on the adalimumab biosimilar market evolution:
Despite being first-to-approval and first-to-interchangeability, Cyltezo entered the market after Amjevita and has faced competitive headwinds in securing preferred formulary positions.
Cyltezo's interchangeable designation means pharmacists in most states can substitute it for Humira without prescriber intervention. Conversely, pharmacists may also substitute away from Cyltezo to a preferred product if allowed by state law and the prescription permits substitution.
If you specifically want your patient on Cyltezo, consider writing "dispense as written" (DAW) — though this may create insurance friction if Cyltezo is non-preferred on the patient's plan.
All FDA-approved adalimumab biosimilars have demonstrated biosimilarity to Humira through rigorous analytical, preclinical, and clinical studies. From a clinical standpoint, switching between adalimumab products does not result in meaningful differences in efficacy or immunogenicity based on available evidence.
The decision to prescribe Cyltezo specifically versus another adalimumab product should be driven by access, cost, and patient preference rather than clinical differentiation.
The Cyltezo Pen Starter Pack uses the same 40 mg/0.4 mL concentration as Humira's citrate-free formulation. Dosing regimens remain the same across adalimumab products for all approved indications. No dose adjustment is required when switching between biosimilars.
Cyltezo's availability challenges stem from several structural factors:
We assign Cyltezo a findability score of 55 out of 100 — meaning it requires active effort to locate and fill, particularly through non-specialty channels.
Cyltezo is priced at approximately $5,800 to $6,500 per monthly supply at list price, representing a 5-15% discount versus Humira's list price of $6,900-$7,200. However, net pricing after rebates varies significantly by plan.
Boehringer Ingelheim offers two key programs:
Many plans require prior authorization for Cyltezo, especially when it's not the preferred adalimumab product. Be prepared to submit clinical documentation supporting the use of Cyltezo specifically, including:
Medfinder for Providers offers real-time medication availability data that can help your office staff and patients locate Cyltezo (or alternatives) in stock at nearby pharmacies. This is particularly useful for patients who need to start therapy quickly.
Consider establishing direct relationships with 2-3 specialty pharmacies that stock Cyltezo. This ensures a reliable channel when you prescribe it. Key specialty pharmacies to evaluate include:
When e-prescribing, use the specific NDC for Cyltezo Pen 40 mg/0.4 mL Starter Pack to avoid confusion at the pharmacy level. Ensure the prescription is routed to a specialty pharmacy rather than a retail location.
The adalimumab biosimilar market is expected to continue evolving through 2026 and beyond. Key trends to watch:
Cyltezo remains a clinically sound adalimumab option backed by interchangeable status and a citrate-free pen formulation. The access challenges your patients face are driven by market dynamics rather than supply problems.
As a prescriber, you can best support your patients by staying informed about formulary changes, maintaining specialty pharmacy relationships, and using tools like Medfinder for Providers to quickly identify available inventory.
For patient-facing resources, consider directing your patients to our articles on finding Cyltezo in stock and saving money on Cyltezo.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
